Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Analyst Optimism | Delve into analyst perspectives, with price targets ranging from $5 to $9, reflecting confidence in Savara's potential despite regulatory challenges |
Financial Fortitude | Learn about Savara's robust financial strategy, combining cash reserves and strategic debt financing to support operations through Molbreevi's anticipated launch |
Market Expansion | Discover how a larger patient population and global market approach position Savara for significant commercial potential in the aPAP treatment landscape |
Molbreevi's Promise | Explore Savara's lead candidate for aPAP treatment, showcasing strong clinical data and potential to revolutionize care for this rare respiratory disease |
Metrics to compare | SVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSVRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.5x | −3.4x | −0.5x | |
PEG Ratio | 1.24 | −0.09 | 0.00 | |
Price / Book | 7.3x | 3.7x | 2.6x | |
Price / LTM Sales | - | 118.0x | 3.2x | |
Upside (Analyst Target) | 68.9% | 69.2% | 47.6% | |
Fair Value Upside | Unlock | 3.0% | 6.1% | Unlock |